Zomedica Corp. (ZOMDF) stock
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Zomedica Corp. grew revenue 31.3% to $38.68M over the twelve months to Sep 30, 2026. Free cash flow was -$11.92M. At the latest close the market valued the company at $77.40M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $77.40M
- P/E ratio
- –
- Price to sales
- 2.00
- Price to book
- 0.74
- Dividend yield
- –
- Free cash flow yield
- -15.40%
Fundamentals
- Revenue
- $38.68M
- Net income
- -$16.00M
- EPS, diluted
- $0.00
- Free cash flow
- -$11.92M
- Book value per share
- $0.11
- Diluted shares
- 980M
Trading
- Next earnings
- Mar 15, 2027 (estimated, during market hours)
- Previous close
- $0.08
- Open
- $0.08
- Day's range
- $0.07 – $0.08
- Volume
- 593,537
- Average volume (20 days)
- 871,944
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZOMDF | S&P 500 | Difference | ZOMDF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.1% | +0.6% | +1.5 pts | ||
| 3 months | -8.2% | +3.4% | −11.5 pts | ||
| Year to date | -22.4% | +13.3% | −35.7 pts | ||
| 1 year | +26.4% | +16.6% | +9.8 pts | ||
| 3 years | -53.5% | +86.4% | −139.9 pts | -22.5% | +23.1% |
| 5 years | -84.5% | +81.9% | −166.4 pts | -31.1% | +12.7% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zomedica filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Zomedica
Pharmaceutical Preparations
Zomedica Corp. is an animal health company that develops, manufactures, and markets diagnostic and therapeutic medical devices for companion animals, including dogs, cats, and horses. Its diagnostic offerings include the TRUFORMA point-of-care acoustic wave testing platform, the TRUVIEW automated digital microscopy and cytology system, and the VETGuardian zero-touch vital signs remote monitoring device. Its therapeutic portfolio features PulseVet electrohydraulic shockwave therapy equipment, Assisi targeted pulsed electromagnetic field devices, and VETIGEL hemostatic gel. The company primarily serves clinical veterinarians, veterinary practices, and pet owners.
Company profile, executives and historyZomedica stock: common questions
What is Zomedica's stock price?
ZOMDF closed at $0.08 on Oct 19, 2026, down 0.55% on the day.
What is Zomedica's market cap?
Zomedica was worth $77.40M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ZOMDF's P/E ratio?
Zomedica lost money over the twelve months to Sep 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Zomedica make?
Zomedica reported revenue of $38.68M for the twelve months to Sep 30, 2026, up 31.3% from a year earlier.
Does Zomedica pay a dividend?
No. Zomedica has not paid a cash dividend over the last twelve months.
When does Zomedica report earnings next?
Zomedica is expected to report Q4 FY2026 results on Mar 15, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ZOMDF stock performed over the past year?
Including dividends, ZOMDF returned +26.4% over the past year, against +16.6% for the S&P 500.
Who are Zomedica's competitors?
Companies most similar to Zomedica by business, industry and size include JAGX, ZYBT, BHST, AQST, LXRX.
See a number that looks wrong?